Omur Gokmen Sevindik

Prof. Dr. Omur Gokmen Sevindik

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
SSSerife Solmaz
Serife Solmaz
OUOzcan Uzun
Ozcan Uzun
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
FDFatih Demirkan
Fatih Demirkan
MOMehmet Ali Ozcan
Mehmet Ali Ozcan
IAInci Alacacıoglu
Inci Alacacıoglu

24 February 2022 in Turkish Journal of Hematology
Verified
Journal Article
Open access
SBSinem Civriz Civriz Bozdag
Sinem Civriz Civriz Bozdag
GSGuldane Cengiz Seval
Guldane Cengiz Seval
IYIpek Yonal-Hindilerden
Ipek Yonal-Hindilerden
FHFehmi Hindilerden
Fehmi Hindilerden
NANeslihan Andıç
Neslihan Andıç
GÖGüner Hayri Özsan
Güner Hayri Özsan
Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly immunosuppressed populations, such as in patients with hematological malignancies, is a point of interest. We aimed to analyze the symptoms, complications, intensive care unit admissions, and mortality rates of patients with hematological malignancies infected with SARS-CoV-2 in Turkey. Materials and Methods: In this multicenter study, we included 340 adult and pediatric patients diagnosed with SARS-CoV-2 from March to November 2020. Diagnosis and status of primary disease, treatment schedules for hematological malignancies, time from last treatment, life expectancy related to the hematological disease, and comorbidities were recorded, together with data regarding symptoms, treatment, and outcome of SARS-CoV-2 infection. Results: Forty four patients were asymptomatic at diagnosis of SARSCoV-2 infection. Among symptomatic patients, fever, cough, and dyspnea were observed in 62.6%, 48.8%, and 41.8%, respectively. Sixtynine (20%) patients had mild SARS-CoV-2 disease, whereas moderate, severe, and critical disease was reported in 101 (29%), 71 (20%), and 55 (16%) patients, respectively. Of the entire cohort, 251 (73.8%) patients were hospitalized for SARS-CoV-2. Mortality related to SARS-CoV-2 infection was 26.5% in the entire cohort; this comprised 4.4% of those patients with mild disease, 12.4% of those with moderate disease, and 83% of those with severe or critical disease. Active hematological disease, lower life expectancy related to primary hematological disease, neutropenia at diagnosis of SARS-CoV-2, ICU admission, and first-line therapy used for coronavirus disease-2019 treatment were found to be related to higher mortality rates. Treatments with hydroxychloroquine alone or in combination with azithromycin were associated with a higher rate of mortality in comparison to favipiravir use. Conclusion: Patients with hematological malignancy infected with SARS-CoV-2 have an increased risk of severe disease and mortality.

1 January 2023 in The Eurasian Journal of Medicine
Verified
Journal Article
Open access
YMYasa Gul Mutlu
Yasa Gul Mutlu
BBBerrin Balık
Berrin Balık
AÇAslı Çakır
Aslı Çakır
ÖCÖzlem Canöz
Özlem Canöz
CECengiz Erol
Cengiz Erol
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
Objective: Surgical excisional biopsy is accepted as the standard of care approach in the diagnosis of lympho- mas. Financial issues related to the increased cost and the invasive nature of the procedure forced physicians to use some alternative diagnostic methods. Percutaneous core needle biopsy, which gained a reputation for the diagnosis of lymphomas with the advent of improved pathological, immunohistochemical, and molecular analysis, made it possible to have an accurate diagnosis with limited tissue samples. In this retrospective study, we aimed to compare the diagnostic yield of surgical excisional biopsy and core needle biopsy. Materials and Methods: This study included 131 patients who were diagnosed with lymphoma with a nodal biopsy which was acquired via surgical excisional biopsy or core needle biopsy between 2014 and 2020 in our center. Around 68 patients underwent surgical excisional biopsy and the remaining 63 underwent core needle biopsy. Samples that allowed to the identification of the exact tumor type and/or subtype were accepted as fully diagnostic. Sufficient amount of tissue that the pathologist could have any suspicious findings considering malignant lymphoma was classified as partial diagnostic group. Inadequate samples were the ones who were not enough to report any final diagnosis. Results: The patients who underwent a core needle biopsy were significantly older than the patients who underwent to surgical excisional biopsy (56.8 vs. 47.6, P = .003). Despite the full diagnostic ability of surgical excisional biopsy outperformed core needle biopsy (95.2 % vs. 83.8 %, P=.035), in 92.6% of the patients whose tissue samples were obtained via core needle biopsy were accepted to have a sufficient diagnosis to initiate the treatment and not required a second biopsy, which was comparable with the ones achieved by surgical excisional biopsy (92.6% vs. 95.2%, P = .720). Conclusion: According to the results obtained in our study, we may conclude that core needle biopsy is a viable and comparable alternative to surgical excisional biopsy, offering a less invasive and less-expansive approach. Cite this article as: Gül Mutlu Y, Balık Aydın B, Çakır A, Canöz Ö, Erol C, Gökmen Sevindik Ö. Should core needle lymph node biopsy be a relevant alternative to surgical excisional biopsy in diagnostic work up of lymphomas? Eurasian J Med., 2023;55(2):114-119.

1 December 2017 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
SKSerdal Korkmaz
Serdal Korkmaz
FAFevzi Altuntas
Fevzi Altuntas

6 March 2015 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
ZGZeynep Guc
Zeynep Guc
SKSelda Kahraman
Selda Kahraman
SSSerife Medeni Solmaz
Serife Medeni Solmaz
AKAbdullah Katgi
Abdullah Katgi
MOMehmet Ali Ozcan
Mehmet Ali Ozcan
The serum albumin (SA) level has been reported to be an independent prognostic biomarker that may serve as a surrogate representative of disease biology in patients diagnosed with myelodysplastic syndrome (MDS). However, its prognostic ability has not been tested in a model adjusting for comorbidities. We analyzed 200 patients who were diagnosed as having de novo MDS. Median overall survival (OS) of all patients was 25 months and median leukemia-free survival (LFS) was 24 months. Median OS according to the SA level groups of ≤ 3.5, 3.6–4.0 and > 4.0 mg/dL were 24, 39 and 77 months, respectively. SA level remained an independent predictor of both LFS and OS even when adjusting for the hematopoietic cell transplant comorbidity index (HCT-CI) and the International Prognostic Scoring System (IPSS) or World Health Organization classification-based Prognostic Scoring System (WPSS). Our findings indicate that SA level at the time of diagnosis is a significant and independent predictor of LFS and OS even when adjusting for commonly used prognostic systems and comorbidities.

18 September 2014 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
AKAbdullah Katgı
Abdullah Katgı
OSOmur Gokmen Sevindik
Omur Gokmen Sevindik
AGAysun Adan Gökbulut
Aysun Adan Gökbulut
GÖGüner Hayri Özsan
Güner Hayri Özsan
FYFaize Yüksel
Faize Yüksel
ÖPÖzden Pişkin
Özden Pişkin
Background: There have been concerns about the possible prothrombotic effects of nilotinib, especially in patients having cardiovascular risk factors. The potential mechanism behind the increased risk of thromboembolic events is still not clear. Objectives: In this study, we aimed to evaluate possible harmful effects of nilotinib on endothelial cells. To this aim, we examined proliferative capacity and secretory functions of healthy human carotid artery endothelial cells (HCtAECs) in response to nilotinib. Methods: 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation method was used to determine antiproliferative effects of nilotinib on HCtAECs. The HCtAECs were incubated with 5, 10, and 100 nmol/L doses of nilotinib for 72 hours. Then, in order to assess the endothelial function, levels of nitric oxide (NO), von Willebrand factor (vWF), tissue plasminogen activator, plasminogen activator inhibitor 1 (PAI-1), and endothelin 1 (ET-1) were evaluated using enzyme-linked immunosorbent assay from tissue culture supernatants. Results: There were slight but statistically significant decreases in cell proliferation in response to nilotinib. Nilotinib increased the secretion of t-PA, PAI-1, and vWF in a dose-dependent manner when compared with the untreated control group. The ET-1 secretion was lower in 5 nmol/L and higher in 10 and 100 nmol/L nilotinib-treated cells as compared to untreated cells. Regarding NO secretion, lower levels were observed in 5 and 10 nmol/L, and higher levels were detected in 100 nmol/L nilotinib-treated cells as compared to untreated control group cells. Conclusion: Considering the results obtained in our study, nilotinib does not affect the functions of endothelial cells either in a prothrombotic or an antithrombotic fashion, despite a dose-dependent decline in cell viability.